Losartan Drug Classification
Losartan belongs to the angiotensin II receptor blocker (ARB) class of medications. 1
Mechanism of Action
Losartan is an orally-active, selective, non-peptide angiotensin II type 1 (AT1) receptor antagonist 1. It works by blocking the AT1 receptor subtype, preventing angiotensin II from binding and exerting its vasoconstrictive and aldosterone-secreting effects 1, 2.
Unique Pharmacological Features
- Active Metabolite: Losartan is rapidly converted via oxidation in the liver to a more potent metabolite (E3174) with 20-30 times greater affinity for the AT1 receptor 2
- Competitive vs Non-competitive Inhibition: The parent compound exhibits competitive inhibition while the E3174 metabolite demonstrates non-competitive inhibition of the AT1 receptor 2
- Half-life: The active metabolite E3174 has a half-life of 6-9 hours, allowing for once-daily dosing 2
Clinical Indications
Losartan is FDA-approved for three primary indications 1:
- Hypertension: Treatment in adults and pediatric patients ≥6 years of age to lower blood pressure 1
- Stroke Risk Reduction: In hypertensive patients with left ventricular hypertrophy (though evidence suggests this benefit does not apply to Black patients) 1, 3
- Diabetic Nephropathy: Treatment in patients with type 2 diabetes, elevated serum creatinine, and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) with a history of hypertension 1
ARB Class Context
Comparison with Other ARBs
Multiple ARBs are available in clinical practice, including candesartan, valsartan, irbesartan, telmisartan, olmesartan, eprosartan, and azilsartan 4, 5, 6, 7, 8. While all ARBs selectively block the AT1 receptor, they differ in:
- Pharmacokinetic/pharmacodynamic profiles 2
- Degree of receptor affinity 2
- Clinical efficacy: Recent network meta-analysis suggests olmesartan and telmisartan may demonstrate superior antihypertensive efficacy compared to losartan 9
Dosing Considerations
Standard dosing ranges 4, 5, 10, 11:
- Initial dose: 25-50 mg once daily
- Target dose: 50-100 mg once daily (or in 1-2 divided doses)
- Maximum dose per FDA labeling: 100 mg daily 4
- ACC/AHA recommended target: 150 mg daily for heart failure, though FDA labeling lists 100 mg as maximum 4
Clinical Use in Specific Conditions
Heart Failure with Reduced Ejection Fraction (HFrEF)
ARBs, including losartan, are recommended as alternatives to ACE inhibitors in patients who cannot tolerate ACE inhibitors due to cough or angioedema 5, 12, 11, 13. The HEAAL trial demonstrated that losartan 150 mg daily was superior to 50 mg daily, emphasizing the importance of achieving target doses 12, 13.
Important caveat: The ELITE II trial failed to show losartan 50 mg daily was as effective as captopril 50 mg three times daily, highlighting the dose-dependent nature of ARB efficacy 12, 13.
Combination with ACE Inhibitors
Simultaneous use of an ACE inhibitor, ARB, and/or renin inhibitor is potentially harmful and not recommended 6, 7. However, adding an ARB to ACE inhibitor therapy in heart failure may modestly reduce hospitalizations, though with increased risk of hyperkalemia and renal dysfunction 5, 11.
Safety Considerations
Key Contraindications and Warnings 1:
- Pregnancy: Black box warning - can cause injury or death to unborn babies; discontinue immediately if pregnancy detected 1
- Diabetes with aliskiren use: Do not combine 1
- Angioedema history: Use extreme caution; while less common than with ACE inhibitors, cross-reactivity can occur 5, 11
Monitoring Requirements 6, 7, 8:
- Hyperkalemia risk: Particularly in patients with CKD or those taking potassium supplements, potassium-sparing diuretics, or aldosterone antagonists 6, 7, 8
- Renal function: Risk of acute renal failure in patients with severe bilateral renal artery stenosis 6, 7
- Hypotension: May cause symptomatic low blood pressure, especially in volume-depleted patients 1
Potassium Content
Each losartan tablet contains potassium: 25 mg tablet = 2.12 mg (0.054 mEq), 50 mg tablet = 4.24 mg (0.108 mEq), 100 mg tablet = 8.48 mg (0.216 mEq) 1.